These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 16728533

  • 1. Insulin-sensitizing agents in polycystic ovary syndrome.
    Pasquali R, Gambineri A.
    Eur J Endocrinol; 2006 Jun; 154(6):763-75. PubMed ID: 16728533
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Insulin-sensitizing agents in women with polycystic ovary syndrome.
    Pasquali R, Gambineri A.
    Fertil Steril; 2006 Jul; 86 Suppl 1():S28-9. PubMed ID: 16798283
    [Abstract] [Full Text] [Related]

  • 8. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.
    Sharma ST, Nestler JE.
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):245-60. PubMed ID: 16772155
    [Abstract] [Full Text] [Related]

  • 9. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
    Orbetsova M, Kamenov Z, Kolarov G, Zakharieva S, Khristov V, Atanasova I, Shigarminova R, Milcheva B, Genchev G.
    Akush Ginekol (Sofiia); 2006 Jun; 45(7):16-28. PubMed ID: 17489164
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis.
    Tang Z, Guan J, Mao JH, Han L, Zhang JJ, Chen R, Jiao Z.
    Eur J Pharm Sci; 2023 Nov 01; 190():106577. PubMed ID: 37666459
    [Abstract] [Full Text] [Related]

  • 18. The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.
    Katsiki N, Georgiadou E, Hatzitolios AI.
    Drugs; 2009 Jul 30; 69(11):1417-31. PubMed ID: 19634921
    [Abstract] [Full Text] [Related]

  • 19. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
    Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH.
    Hum Reprod; 2006 Jan 30; 21(1):80-9. PubMed ID: 16199429
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.